Update on gout: new therapeutic strategies and options

被引:291
作者
Terkeltaub, Robert [1 ]
机构
[1] Univ Calif San Diego, Vet Affairs Med Ctr, Rheumatol Sect, La Jolla, CA 92161 USA
关键词
TREATMENT-FAILURE GOUT; PLACEBO-CONTROLLED TRIALS; URIC-ACID LEVELS; QUALITY-OF-LIFE; DOUBLE-BLIND; PEGLOTICASE PGL; NALP3; INFLAMMASOME; PARALLEL-GROUP; ALLOPURINOL; URATE;
D O I
10.1038/nrrheum.2009.236
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gout, a disease recognized since antiquity, has increased in prevalence in recent years and the clinical profile of this disease has become increasingly complex, owing to large numbers of cases with iatrogenic factors, multiple comorbidities, advanced age, and hyperuricemia and arthritis refractory to treatment. In this Review, key advances in gout research made during the past decade are summarized. Revised strategies for safe and effective employment of dietary measures and pharmacologic treatments for active gouty arthritis, prevention of gout flares and urate lowering are also reviewed, with an emphasis on dosing of colchicine and allopurinol, and the evidence-based approach to systemic glucocorticosteroid treatment of acute gout. Also discussed are new and emerging treatments for gout and hyperuricemia, and the potential influence of dual energy CT imaging on treatment. In this context, the therapeutic role of febuxostat, and clinical development of pegylated uricase urate-lowering therapy and interleukin 1 antagonism for gouty inflammation are reviewed. Collectively, novel approaches will hopefully lead to improved management of hyperuricemia and gout, and also to improvements in patient-centered outcomes, even for those who have previously failed to respond to treatment.
引用
收藏
页码:30 / 38
页数:9
相关论文
共 65 条
[1]   Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans [J].
Anzai, Naohiko ;
Ichida, Kimiyoshi ;
Jutabha, Promsuk ;
Kimura, Toru ;
Babu, Ellappan ;
Jin, Chun Ji ;
Srivastava, Sunena ;
Kitamura, Kenichiro ;
Hisatome, Ichiro ;
Endou, Hitoshi ;
Sakurai, Hiroyuki .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (40) :26834-26838
[2]  
Baraf HS, 2008, ARTHRITIS RHEUM, V58, pS176
[3]  
BECKER M, 2008, ARTHRITIS RHEUM S, V58
[4]  
Becker MA, 2008, ARTHRITIS RHEUM, V58, pS880
[5]   Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].
Becker, MA ;
Schumacher, HR ;
Wortmann, RL ;
MacDonald, PA ;
Eustace, D ;
Palo, WA ;
Streit, J ;
Joseph-Ridge, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461
[6]   Quality of Life and Disability in Patients with Treatment-Failure Gout [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
Benjamin, Katy L. ;
Gorevic, Peter ;
Greenwald, Maria ;
Fessel, Jeffrey ;
Edwards, Lawrence ;
Kawata, Ariane K. ;
Frank, Lori ;
Waltrip, Royce ;
Maroli, Allan ;
Huang, Bill ;
Sundy, John S. .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (05) :1041-1048
[7]   On the brink of novel therapeutic options for an ancient disease [J].
Bieber, JD ;
Terkeltaub, RA .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2400-2414
[8]  
Borstad GC, 2004, J RHEUMATOL, V31, P2429
[9]   Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI [J].
Brandstaetter, Anita ;
Kiechl, Stefan ;
Kollerits, Barbara ;
Hunt, Steven C. ;
Heid, Iris M. ;
Coassin, Stefan ;
Willeit, Johann ;
Adams, Ted D. ;
Illig, Thomas ;
Hopkins, Paul N. ;
Kronenberg, Florian .
DIABETES CARE, 2008, 31 (08) :1662-1667
[10]   Comparison of drug adherence rates among patients with seven different medical conditions [J].
Briesacher, Becky A. ;
Andrade, Susan E. ;
Fouayzi, Hassan ;
Chan, Arnold .
PHARMACOTHERAPY, 2008, 28 (04) :437-443